Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Propylthiouracil
Drug ID BADD_D01869
Description A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)
Indications and Usage Used to manage hyperthyroidism which is due to an overactive thyroid gland (Grave's disease).
Marketing Status Prescription; Discontinued
ATC Code H03BA02
DrugBank ID DB00550
KEGG ID D00562
MeSH ID D011441
PubChem ID 657298
TTD Drug ID D00MIN
NDC Product Code 20012-0001; 49452-6112; 65319-1059; 68084-964; 51927-0163; 51927-1183; 59348-0013; 70752-171; 67253-651; 0228-2348
Synonyms Propylthiouracil | 6-Propyl-2-Thiouracil | 6 Propyl 2 Thiouracil
Chemical Information
Molecular Formula C7H10N2OS
CAS Registry Number 51-52-5
SMILES CCCC1=CC(=O)NC(=S)N1
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acute hepatic failure09.01.03.0010.009980%Not Available
Acute respiratory distress syndrome22.01.03.0010.002851%
Ageusia07.14.03.003; 17.02.07.001--Not Available
Agranulocytosis01.02.03.0010.032792%Not Available
Alopecia23.02.02.001--
Anaemia01.03.02.0010.010931%
Aplasia cutis congenita03.05.01.011; 23.01.04.0040.002851%Not Available
Aplastic anaemia01.03.03.002--Not Available
Arteritis24.05.01.001--Not Available
Arthralgia15.01.02.0010.016396%
Aspartate aminotransferase increased13.03.01.0060.010931%
Asthenia08.01.01.0010.010931%Not Available
Blood bilirubin increased13.03.01.0080.016396%
Body temperature increased13.15.01.001--Not Available
Chills08.01.09.001; 15.05.03.0160.010931%
Cough22.02.03.0010.010931%
Deafness neurosensory04.02.01.002; 17.04.07.0010.010931%Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Disseminated intravascular coagulation01.01.02.002; 24.01.01.0100.002851%
Dysgeusia07.14.03.001; 17.02.07.003--
Dyspepsia07.01.02.001--
Dyspnoea02.01.03.002; 22.02.01.0040.016396%
Erythema nodosum10.02.01.020; 23.07.02.001--Not Available
Exomphalos03.04.07.001; 07.16.03.0020.010931%Not Available
Fatigue08.01.01.0020.021861%
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.0090.002851%Not Available
Glomerulonephritis10.02.01.006; 20.05.01.0010.010931%Not Available
Glomerulonephritis rapidly progressive10.04.04.008; 20.05.01.0040.005703%Not Available
Granulocytopenia01.02.03.003--Not Available
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene